Publications
Detailed Information
Brain metabolite alterations in subjects at ultra-high risk for psychosis: magnetic resonance spectroscopy study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Byun, M. | - |
dc.contributor.author | Choi, J. | - |
dc.contributor.author | Yoo, S. | - |
dc.contributor.author | Kang, D. | - |
dc.contributor.author | Jang, D. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Kwon, J. | - |
dc.contributor.author | Jung, W. | - |
dc.contributor.author | Choi, C. | - |
dc.date.accessioned | 2012-07-05T02:09:24Z | - |
dc.date.available | 2012-07-05T02:09:24Z | - |
dc.date.issued | 2009-09 | - |
dc.identifier.citation | EUROPEAN NEUROPSYCHOPHARMACOLOGY; Vol.19 ; S311-S312 | ko_KR |
dc.identifier.issn | 0924-977X | - |
dc.identifier.uri | https://hdl.handle.net/10371/78557 | - |
dc.description.abstract | Recent neuroirnaging studies have suggested that brain changes
occur in subjects at ultra-high risk (UHR) for psychosis while experiencing prodromal symptoms, among which depression may increase the risk of developing a psychotic disorder. We used proton magnetic resonance spectroscopy to examine brain metabolite levels in the anterior cingulate cortex, the left dorsolateral prefrontal cortex and the left thalamus in subjects at UHR for psychosis. In addition, we compared brain metabolites between the UHR subjects with comorbid major depressive disorder (MDD) and healthy controls. Twenty UHR subjects and 20 age- and IQ-matched healthy controls were included in this study. UHR was determined based on the Comprehensive Assessment of At-Risk Mental States (CAARMS) criteria [1]. At intake, all potential subjects participated in an intensive clinical interview with two experienced psychiatrists who used the Structured Clinical Interview for DSM-IV Axis I section (SCID) to identify past and current psychiatric illnesses. Eleven subjects in the UHR group (55%) were diagnosed with comorbid MDD, eight with anxiety disorder, and one with bipolar disorder. A modified 24-item version of the Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS), the Hamilton Rating Scale for Depression (HAM-D), and the Hamilton Rating Scale for Anxiety (HAM-A), the Korean version of the Wechsler Adult Intelligence Scale (K-WAIS) were also used to assess the participants. Subjects were longitudinally monitored for progression to psychosis. The UHR group was subsequently divided into two subgroups: UHRpsychotic (n = 2) and UHR-nonpsychotic (n = 17). Nine subjects were receiving psychotropic drugs at baseline (low-dose atypical antipsychotics, n = 8; antidepressant, n = 1). No significant differences were observed between the UHR and healthy control groups in terms of age, sex ratio, or IQ. Compared to the UHR subjects without MDD (n = 9), UHR subjects with MDD (n = 11) scored significantly higher on the PANSS total (60.00±5.98, p=0.012), BPRS (46.55±3.67, p=0.014), and HAM-D (17.18±4.24, p=0.046). There were no significant differences in any other metabolite level in any brain region among UHR subjects with MDD, UHR subjects without MDD, or healthy controls. However, UHR subjects with MDD showed significantly higher myo-inositol (Ins) levels in the left thalamus, compared to the healthy control (Ins: 3.33±0.63mM versus 2.58±0.71 mM, F=3.825, p=0.031). Additional analysis in drug-naive UHR subjects (n = 11) to control the effect of medication revealed significantly increased Ins concentrations in the left thalamus of drug-naive UHR subjects compared to healthy controls (Ins: F=5.032, p=0.033). However, a significant comorbidity effect was observed for Ins concentrations in the left thalamus among drug-naive UHR subjects with MDD, those without MDD, and healthy controls (Ins: F = 3.656, p = 0.039), although the sample size was small. There was no significant difference in any metabolites concentrations between UHR subjects who progressed to psychosis and subjects who did not. Our results demonstrate that increased thalamic Ins level is associated with prodromal depressive symptoms. Further longitudinal follow-up studies with larger UHR sample sizes are required to investigate the function of Ins concentrations as a biomarker of vulnerability to psychosis. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCIENCE BV | ko_KR |
dc.title | Brain metabolite alterations in subjects at ultra-high risk for psychosis: magnetic resonance spectroscopy study | ko_KR |
dc.type | Article | ko_KR |
dc.citation.journaltitle | EUROPEAN NEUROPSYCHOPHARMACOLOGY | - |
dc.description.citedreference | Yung AR, 2005, AUST NZ J PSYCHIAT, V39, P964 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.